Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma-Reference-Cited by-同舟云学术

Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma

Published:2024-08-26 Issue:1 Volume:13 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

De Falco Vincenzo¹^ORCID,Napolitano Stefania¹^ORCID,Franco Renato²,Zito Marino Federica²,Formisano Luigi³,Esposito Daniela³,Suarato Gabriella¹,Napolitano Rossella¹,Esposito Alfonso¹,Caraglia Francesco¹,Giugliano Maria Cristina¹,Cioli Eleonora¹,Famiglietti Vincenzo¹,Bianco Roberto³,Argenziano Giuseppe⁴,Ronchi Andrea²,Ciardiello Davide¹⁵,Nardone Valerio⁶,D’Ippolito Emma⁶,Del Tufo Sara⁶,Ciardiello Fortunato¹,Troiani Teresa¹^ORCID

Affiliation:

1. Medical Oncology Unit, Department of Precision Medicine, Università della Campania “Luigi Vanvitelli”, Naples, Italy

2. Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, via Luciano Armanni, Naples, Italy

3. Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Napoli, Italy

4. Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy

5. Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy

6. Radiology Unit, Department of Precision Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2024.2388315

Reference24 articles.

1. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention

2. Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC)

3. Signatures of mutational processes in human cancer

4. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

5. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma